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with their normal work. After 3 months, these percentages
changed to 58.5 and 81.8% in the cognitive-behavioral
therapy (CBT) and control groups, respectively.
The relationship between pain and depression in end-stage
renal disease patients is important. The impact of CBT in
alleviating body pain in these patients requires future research.
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Sudden cardiac death and mineral
metabolism in chronic kidney
disease
Pun et al. showed that reductions in the estimated glomerular
ﬁltration rate (eGFR) were associated with an increase in the
risk of sudden cardiac death in a graded fashion in patients
with coronary artery disease. The authors claimed that
decreased eGFR induces many metabolic and physiological
changes that might be responsible for increased sudden
cardiac death in chronic renal failure patients.1 Although the
study is informative, we are especially concerned about the
relationship between calcium, phosphorus, Ca P product,
parathyroid hormone levels, and sudden cardiac death in the
study population. It is well established that abnormalities in
mineral metabolism are apparent early in the course of
chronic kidney disease (CKD). Beginning in CKD stage 3, the
ability of the kidneys to appropriately excrete a phosphate
load is diminished, leading to hyperphosphatemia, elevated
parathyroid hormone, and decreased vitamin D levels.
Furthermore, there is emerging evidence linking some of
these abnormalities (for example, hyperphosphatemia and
hypercalcemia) to the high cardiovascular morbidity and
mortality experienced by nondialyzed patients with CKD.
One of the mechanisms for deranged mineral metabolism
to induce cardiovascular disorders is thought to be the
calciﬁcation of the vascular tree that result in arterial stiffness.
Arterial stiffness of the large arteries has important clinical
consequences: raised systolic blood pressure, increased pulse
pressure, left ventricular hypertrophy, and reduced coronary
perfusion.2,3
Experimental evidence showed that high levels of phos-
phate and/or calcium directly activated genes related to an
osteoblastic phenotype in the smooth muscle cells.4 In
addition, elevated phosphorus and calcium stimulated the
transformation of vascular smooth muscle cells into osteo-
blast-like cells in vitro using cell-culture techniques.5 Besides,
clinical evidence also suggests that high pre-dialysis serum
phosphate is a powerful predictor of sudden cardiac death.6
Since the regular control of calcium, phosphorus, and
parathyroid hormone in chronic renal failure patients is
strongly recommended, if available, the presently informative
results by Pun et al. would have been much more valuable
with the addition of parameters of mineral metabolism in the
adjusted analyses.
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The Authors Reply: We appreciate Drs Afsar and Elsurer
for their interest and comments about our study.1 We agree
that disordered mineral metabolism has been associated
with cardiac risk in hemodialysis patients,2 in those with less
severe chronic kidney disease,3 and in some patients who
lack overt kidney disease.4 We now report available laboratory
data on serum calcium, phosphorus, and parathyroid
hormone (PTH) concentrations obtained within 3 months
prior to cardiac catheterization in the study cohort.
Concurrent PTH data were unavailable on the majority of
patients, but calcium and phosphorus data were available in
46% of patients with glomerular ﬁltration rate (GFR) o15
and in 18% of patients with GFRX15 (Table 1). Calcium and
calcium–phosphorus product had no signiﬁcant relationship
with the composite outcome, but phosphorus had a
signiﬁcant relationship (hazard ratio 1.27, 95% conﬁdence
interval 1.04–1.55) in univariate analysis. However, this
relationship was abolished after accounting for baseline
GFR. Accounting for serum phosphorus did not alter the
relationship between GFR and outcome in an adjusted model.
Therefore, our study ﬁndings could not be explained by
measured abnormalities in mineral metabolism, although the
analysis was limited by missing data.
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Although the relationship between markers of disordered
mineral metabolism and cardiovascular mortality is established,
the relationship with sudden cardiac death (SCD) is less clear.
Karnik et al.5 found that hemodialysis patients who experi-
enced a witnessed cardiac arrest had lower serum phosphorus
levels than population controls, and we previously reported no
signiﬁcant relationship between serum calcium, phosphorus
and PTH levels, and survival following a witnessed peridialytic
cardiac arrest.6 Prospective randomized studies are needed to
examine the effect of current therapeutic options for abnormal
mineral metabolism and cardiovascular beneﬁt, including SCD.
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Taste disturbance by
angiotensin-converting
enzyme inhibitors/angiotensin-2
receptor blockers
To the Editor: We read with interest the recent article by
Kusaba et al.1 The authors found that both recognition and
detection thresholds were increased in patients with chronic
kidney disease (CKD). They also found that patients with
diabetic nephropathy had a higher detection threshold than
non-diabetic patients with CKD. In this regard, one has to
consider the taste disturbance caused by angiotensin-
converting enzyme inhibitors (ACEIs) and angiotensin-2
receptor blockers (ARBs).2,3 The authors reported that ACEIs
and/or ARBs were prescribed for 72% of the patients with
CKD. This could explain the higher taste thresholds in CKD.
Similarly, it should be noted that ACEIs and/or ARBs are
more likely to be prescribed for patients with diabetic
nephropathy than for patients without diabetes mellitus.
Although the authors stated no difference in taste thresholds
based on the administration of antihypertensives except for
diuretics, the numbers obtained by comparison (22 versus 7)
do not yield enough statistical power. Therefore, we are
concerned about the effects of ACEIs and/or ARBs mentioned
in the study.
It is of interest that the recognition threshold for salty taste
was recovered after 1 week of sodium restriction. This
recovery may be unrelated to ACEI and/or ARB use. The
authors should clarify whether there was a change in ACEI
and/or ARB use during the 1 week of sodium restriction.
That there was no signiﬁcant difference in discrimination
threshold between before and after the sodium restriction
may be due to ACEI and/or ARB use. Further studies without
ACEI and ARB use are therefore warranted.
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The Authors Reply: We appreciate the interest of Drs
Ebihara and Kohzuki1 regarding our paper.2 We present here
our reply per their request.
First, regarding the effect of angiotensin-converting enzyme
inhibitors (ACEIs) and angiotensin-2 receptor blockers
(ARBs) on taste disturbance, these drugs were administered
to 21 patients (72%) in our study. We further analyzed the
effects of these drugs, which revealed that the recognition
threshold for salty taste was 0.91±0.31% for patients who
were administered these drugs and 0.80±0.11% for those who
Table 1 | Baseline characteristics of the study cohort
GFR X60 GFR 15–59 GFR o15
Number 14,652 4364 424
Median calcium (mg/dl) 8.7 8.7 8.8
No. of subjects with data (%) 2618 (18%) 809 (19%) 196 (46%)
Median phosphorus (mg/dl) 3.3 3.6 5.0
No. of subjects with data (%) 2504 (17%) 782 (18%) 203 (48%)
Calciumphosphorus 29 31 46
No. of subjects with data (%) 2424 (17%) 750 (17%) 195 (46%)
Abbreviation: GFR, glomerular filtration rate.
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